W H AT W E D O : M AT E R I A L S C I E N C E 5 CUSTOM FORMULATION F E B R U A R Y 1 5 , 2 0 2 3 W E B C A S T Q4 2022 VS. Avient Specialty Formulators Other Specialty / Chemical Companies 2023E(%) 31 79 87 81 79 76 73 90 77 76 75 73 64 59 33 A vi e n t K W R P P G F U L A V Y R P M F M C C E A S H H X L E C L H U N E M N S C L M U LT I P L E E X PA N S I O N Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of February 13, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $38.89. Avient 2011 and 2018 valuations reflect trailing 12 months EBITDA at December 31 of the respective years. 32 EV / 2023E EBITDA Historic Multiple 6.5 8.3 10.0 15.6 13.9 13.7 12.8 9.5 18.0 17.5 12.3 10.2 9.7 8.8 8.4 5.9 A vi e n t (2 0 1 1 ) A vi e n t (2 0 1 8 ) A vi e n t K W R P P G R P M A V Y F U L H X L E C L F M C A S H S C L H U N E M N C E R A W M AT E R I A L O V E R V I E W 34 RAW MATERIAL 2022 ANNUAL PURCHASES Performance Additives 16% Pigments 12% TiO2 11% Dyestuffs 2% Polyethylene 12% Nylon 6% Polypropylene 6% Styrenic Block Copolymer 5% Other Raw Materials 30% ~40% hydrocarbon based (Grey shaded materials are hydrocarbon based, includes portion of “Other Raw Materials”) Non-hydrocarbon based materials Excludes Avient Protective Materials SEGMENT DATA U.S. & Canada 40% EMEA 37% Asia 18% Latin America 5% 2022 PRO FORMA SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 20% Packaging 24% Industrial 15% Building and Construction 10% Telecommunications 4% Energy 4% Defense 6% END MARKET REVENUE (1) Total company adjusted EBITDA of $592M includes corporate costs $2,355M $402M $1,300M $272M Sales EBITDA Specialty Engineered Materials Color Additives and Inks $592M$3,653M (1) Transportation 9% Healthcare 8% 36 C O L O R , A D D I T I V E S & I N K S 2 0 2 2 R E V E N U E | $ 2 . 4 B I L L I O N US & Canada 34% EMEA 38% Asia 20% Latin America 8% END MARKET REGION 37 Packaging 34% Consumer 21% Healthcare 8% Industrial 15% Transportation 8% Building & Construction 11% Telecommunications 1% Energy 2% S P E C I A L T Y E N G I N E E R E D M A T E R I A L S 2 0 2 2 P R O F O R M A R E V E N U E | $ 1 . 3 B I L L I O N END MARKET US & Canada 52% EMEA 35% Asia 13% REGION 38 Packaging 5% Consumer 19% Healthcare 8%Industrial 16% Transportation 10% Telecommunications 10% Energy 9% Defense 15% Building & Construction 8% Packaging 32% Consumer 27% Healthcare 8% Industrial 14% Building & Construction 5% Telecommunications 3% Energy 1% Defense 1% Asia (18% of sales) Transportation 9% 2 0 2 2 P R O F O R M A AV I E N T R E G I O N A L S A L E S B Y E N D M A R K E T Packaging 27% Consumer 14% Healthcare 5% Industrial 17% Building & Construction 10% Energy 5% Defense 8% EMEA (37% of sales)Transportation 11% Packaging 13% Consumer 24% Healthcare 12% Industrial 15% Building & Construction 13% Energy 5% Defense 5% US & Canada (40% of sales) Transportation 7% Packaging 56% Consumer 23% Healthcare 4% Industrial 7% Building & Construction 4% Telecommunications 1% LATAM (5% of sales) Transportation 5% Telecommunications 3% Telecommunications 6% 39

For the plastics used in these medical applications, this can mean compliance with the relevant chapters of the International Organization for Standardization (ISO), the United States Pharmacopeia Class VI (USP VI) the European Pharmacopeia (EP 3.1), and the International Conference on Harmonization (ICH Q3D) standards and guidelines. The raw materials are pre-tested to the relevant chapters of ISO 10991, USP 661, USP Class VI, EP 3.1 and to the ICH Q3D guidelines to help manufacturers increase the certainty of regulatory compliance for their devices and packaging.

W H O W E A R E – V I S I O N , S T R AT E G Y, C U LT U R E 3 Avient Corporation (NYSE: AVNT) provides specialized and sustainable material solutions that transform customer challenges into opportunities, bringing new products to life for a better world. W H AT W E D O : M AT E R I A L S C I E N C E 4 CUSTOM FORMULATION We sell solutions not commodities. Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 26 Capex / Revenue 2021E (%) AV I E N T I S A SS E T L I G H T Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 2 3 3 4 3 3 3 4 4 5 5 5 6 7 7 8 24 A vi e n t A vi e n t (E xc l.

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 26 Capex / Revenue 2022E (%) AV I E N T I S A SS E T L I G H T Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 3 3 4 3 3 5 5 5 7 7 7 A vi e n t A vi e n t (E xc l. D is t. ) K W R P P G F U L R P M A V Y F M C H U N H X L S C L E C L E M N C E A S H Source: Peer data per Bloomberg market data as of February 15, 2022. O U R VA LUATI O N V E R S U S P E E R S Avient Specialty Formulators Other Chemical/Specialty Companies 5.4 8.5 10.1 10.0 15.7 15.0 14.2 12.7 10.2 25.0 19.7 17.7 13.2 12.3 10.0 9.9 8.9 8.5 8.3 6.6 A vi e n t (2 0 1 1 ) A vi e n t (2 0 1 6 ) A vi e n t (2 0 2 1 ) A vi e n t (T o d a y) R P M K W R P P G A V Y F U L A L B E C L H X L A S H F M C B N R E M N U N V R C E S C L H U N Historic Multiple S U M M A RY: W H Y I N V E S T I N AV I E N T ?

HI-VIS GREEN X ET 33731 50% GF HDPE Base

These colorants and additives are pre-certified to meet USP Class VI or ISO 10993 biocompatibility testing for global healthcare applications, such as medical devices, pharmaceutical, and health & wellness products. We can now offer expanded resin families that incorporate biocompatible functional additives, in both masterbatch and compounded forms, that meet or exceed industry standards for USP Class VI or ISO 10993 biocompatibility testing.”

WHITE PP W/ UV/AM D4020A DARK GREEN UV CPSC

055OR2020 ORANGE W/UV TP BLUE UV FDA

UV Royal Blue Grid TEAL W/UV AO

SUBLIME BRONZE W/UV BLANCO NIEVE ABS CON UV